2024
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children
Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Hererra A, Friedberg J, Friedman D, Schwartz C, Pei Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constine L, Hodgson D. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. JAMA Network Open 2024, 7: e2351062. PMID: 38241048, PMCID: PMC10799264, DOI: 10.1001/jamanetworkopen.2023.51062.Peer-Reviewed Original ResearchConceptsCardiac toxic effectsMediastinal RTHodgkin lymphomaRadiation therapyCumulative incidenceCardiac diseaseDoxorubicin doseCohort studyClinical trialsMedian mean heart doseChildren's Oncology Group clinical trialStudy populationHigh-risk HLMean heart dosePlanned cumulative doseRadiation therapy useIncidence of cardiac diseaseCumulative doxorubicin doseRisks associated with treatmentNorth American trialsGroup clinical trialFollow-up guidelinesStandard treatment groupToxic effectsMaintained long term
2023
Prognostic value of chest x‐ray‐ and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831
Lo A, Lee I, Pei Q, Wu Y, McCarten K, Hoppe B, Hodgson D, Roberts K, Milgrom S, Kessel S, Cole P, Kelly K, Cho S. Prognostic value of chest x‐ray‐ and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831. Pediatric Blood & Cancer 2023, 70: e30452. PMID: 37243975, PMCID: PMC10546608, DOI: 10.1002/pbc.30452.Peer-Reviewed Original ResearchConceptsRelapse-free survivalLarge mediastinal adenopathySlow early responseInferior relapse-free survivalWorse relapse-free survivalMediastinal mass ratioPediatric Hodgkin lymphomaHodgkin's lymphomaMediastinal adenopathyPrognostic valueAdvanced-stage HL patientsChildren's Oncology Group studyChest X-rayHazard ratioHL patientsMedian agePoor prognosisChest radiographsMass volumeMass diameterPatientsML/Group studyCTEarly responseRadiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group
Mailhot Vega R, Harker-Murray P, Forlenza C, Cole P, Kelly K, Milgrom S, Parikh R, Hodgson D, Castellino S, Kahn J, Roberts K, Constine L, Hoppe B. Radiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: 400-403. PMID: 37116589, PMCID: PMC10655744, DOI: 10.1016/j.ijrobp.2023.04.022.Peer-Reviewed Original Research
2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group
Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2021, 112: 890-900. PMID: 34767937, PMCID: PMC9038118, DOI: 10.1016/j.ijrobp.2021.10.152.Peer-Reviewed Original ResearchConceptsInvolved-field radiation therapySlow early responseClassical Hodgkin lymphomaBulky diseaseOncology GroupHodgkin's lymphomaRetrospective analysisChildren's Oncology Group protocolsHigh-risk Hodgkin lymphomaRadiation treatment volumesCycles of doxorubicinHigh-risk patientsPhase 3 studyTime of progressionChildren's Oncology GroupPatterns of failureInitial siteABVE-PCConsolidation RTEligible patientsField relapseInitial relapseMedian followRelapse siteStage IIIB
2020
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG
Binkley M, Rauf M, Milgrom S, Pinnix C, Tsang R, Dickinson M, Ng A, Roberts K, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras J, Wright C, Kelsey C, Brady J, Mikhaeel N, Hoppe B, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig J, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine L, Eich H, Wirth A, Hoppe R. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood 2020, 135: 2365-2374. PMID: 32211877, DOI: 10.1182/blood.2019003877.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHodgkin DiseaseHumansKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingNeoplasms, Radiation-InducedNeoplasms, Second PrimaryPositron Emission Tomography Computed TomographyProgression-Free SurvivalProportional Hazards ModelsRecurrenceRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalOverall survivalImmunoarchitectural patternsAssociated with worse progression-free survivalFive-year PFSLymphocyte-predominant Hodgkin lymphomaProgression-free survival ratesStudy of adult patientsSingle-agent rituximabLarge-cell transformationStage I diseaseMedian follow-upMulticenter retrospective studyMulti-institutional studyHodgkin lymphomaI diseaseRT cohortHistological variantsMedian agePrimary managementRetrospective studyRituximabAdult patientsRadiotherapy
2019
Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group
Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. British Journal Of Haematology 2019, 187: 39-48. PMID: 31180135, PMCID: PMC6857800, DOI: 10.1111/bjh.16014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCyclophosphamideDoxorubicinDrug Administration ScheduleDrug MonitoringEtoposideFemaleHodgkin DiseaseHumansIfosfamideMaleNeoplasm StagingPositron-Emission TomographyPrednisoneProspective StudiesRadiotherapy, AdjuvantRecurrenceTreatment OutcomeVincristineVinorelbineYoung AdultConceptsHigh-risk Hodgkin lymphomaABVE-PCOncology GroupHodgkin's lymphomaEarly respondersRapid early respondersEnd of chemotherapyEvent-free survivalOverall survival rateResponse-adapted therapyChildren's Oncology GroupTreatment of childrenPET-positive lesionsAlkylator exposureOS ratesActive diseaseTreat analysisPediatric patientsRadiotherapy volumeClinical evidenceEarly progressionRadiation volumeRecent trialsPositive lesionsSER patients
2016
Adjuvant chemotherapy and overall survival in adult medulloblastoma
Kann BH, Lester-Coll NH, Park HS, Yeboa DN, Kelly JR, Baehring JM, Becker KP, Yu JB, Bindra RS, Roberts KB. Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncology 2016, 19: 259-269. PMID: 27540083, PMCID: PMC5464064, DOI: 10.1093/neuonc/now150.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCerebellar NeoplasmsChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCraniospinal IrradiationFemaleFollow-Up StudiesHumansMaleMedulloblastomaMiddle AgedNeoplasm StagingPrognosisRadiotherapy, AdjuvantSurvival RateYoung AdultConceptsGy craniospinal irradiationCraniospinal irradiationOverall survivalM0 patientsAdjuvant chemotherapyAdult MBMultivariable Cox proportional hazard modelingHigh-dose craniospinal irradiationNational Cancer Data BaseCox proportional hazard modelingSuperior overall survivalPlanned subgroup analysisMultivariable logistic regressionNational database analysisLog-rank testProportional hazard modelingPediatric medulloblastoma patientsCSI dosesPostoperative chemotherapySurgical resectionSurvival impactYear OSMultivariable analysisSubgroup analysisRisk factors
2012
Historical Trends in the Use of Radiation Therapy for Pediatric Cancers: 1973-2008
Jairam V, Roberts KB, Yu JB. Historical Trends in the Use of Radiation Therapy for Pediatric Cancers: 1973-2008. International Journal Of Radiation Oncology • Biology • Physics 2012, 85: e151-e155. PMID: 23273995, PMCID: PMC3636568, DOI: 10.1016/j.ijrobp.2012.10.007.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBone NeoplasmsChildChild, PreschoolFemaleHodgkin DiseaseHumansInfantInfant, NewbornLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMaleNeoplasmsNeuroblastomaOsteosarcomaPrecursor Cell Lymphoblastic Leukemia-LymphomaRadiotherapyRetinoblastomaSEER ProgramSoft Tissue NeoplasmsTime FactorsUnited StatesWilms TumorYoung AdultConceptsUse of RTSoft tissue cancerNon-Hodgkin lymphomaRT useAcute lymphoblastic leukemiaAcute myeloid leukemiaRadiation therapyHodgkin's lymphomaLymphoblastic leukemiaMyeloid leukemiaWilms tumorBrain cancerNational Cancer Institute's SurveillanceExternal beam radiation therapyEnd Results (SEER) databasePercentage of patientsSEER 9 databaseBeam radiation therapyTumor RegistryInitial treatmentResults databaseCombination therapyDiagnosis groupsPediatric cancerJoint cancerPatterns of subsequent malignancies after Hodgkin lymphoma in children and adults
Omer B, Kadan‐Lottick N, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. British Journal Of Haematology 2012, 158: 615-625. PMID: 22775513, DOI: 10.1111/j.1365-2141.2012.09211.x.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsStandardized incidence ratiosSolid second malignant neoplasmsExtended field radiotherapyRecent treatment optionsLow-dose radiationSMN riskSubsequent malignanciesModality therapyIncidence ratiosHodgkin's lymphomaTreatment optionsMalignant neoplasmsSubgroup analysisCMT groupLower incidenceHigh riskGeneral populationAlkylator chemotherapyPatientsDose radiationRiskRadiotherapyChildrenAdults
2011
Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis
Buscariollo DL, Park HS, Roberts KB, Yu JB. Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer 2011, 118: 4212-4219. PMID: 22213196, DOI: 10.1002/cncr.27373.Peer-Reviewed Original ResearchConceptsAtypical teratoid rhabdoid tumorMedian overall survivalOverall survivalRT useLandmark analysisRhabdoid tumorRare central nervous system malignanciesNational Cancer Institute's SurveillanceCentral nervous system malignanciesCox proportional hazards modelRole of radiotherapyEnd Results (SEER) databaseEnd Results analysisSignificant survival benefitProspective clinical trialsGross total resectionPatients ages 4Nervous system malignanciesImmortal time biasProportional hazards modelLong-term survivorshipAdjuvant radiotherapyInitial radiotherapyPrimary endpointInitial management